Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.45 +0.19 (4.46%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Arena Pharma (ARNA) Gains; Reports Results of Investigational Pilot Study of ...  StreetInsider.com (subscription)
Eisai Announces Top-Line Results of Investigational Study on ...  Japan Corporate News (press release)
Related articles »  
Trader's Buzz: Unilife Corporation (UNIS), Arena Pharmaceuticals (ARNA ...
ARNA shares recently gained $0.01 to $4.36. The stock is down more than 2.22% year-over-year and has lost roughly 24.79% year-to-date.
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Arena Investors Need To Watch Contrave Launch Closely
Arena Pharmaceuticals (NASDAQ:ARNA) investors now have something else to pay attention to. Orexigen ... Eisai may need to at some point, but I expect the company to be conservative and to collect some data before jumping to a rash conclusion.
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »  
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »  
Pfizer Setback Could Help Arena
It was only a month ago that the company received positive indications from the FDA when the regulators agreed to a new label for the drug that was less stringent than the earlier label.
Related articles »  
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot ...
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, USA I October 28, 2014 I Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when ...
4 High-Gross Margin Stocks: Arena Pharmaceuticals, Inc. (ARNA), Gastar ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has return on equity ratio of -54.10%. The company has $881.56 million in market worth.
Related articles »